Abbott Laboratories (NYSE:ABT) Updates FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.380-5.580 for the period, compared to the consensus earnings per share estimate of 5.550. The company issued revenue guidance of -. Abbott Laboratories also updated its Q2 2026 guidance to 1.250-1.310 EPS.

Abbott Laboratories Stock Performance

ABT stock opened at $95.08 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $165.59 billion, a price-to-earnings ratio of 25.56, a P/E/G ratio of 1.62 and a beta of 0.79. Abbott Laboratories has a 12 month low of $93.92 and a 12 month high of $139.06. The firm has a 50 day moving average of $108.17 and a two-hundred day moving average of $119.01.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Argus decreased their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Leerink Partners decreased their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $134.00.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 results narrowly beat expectations: adjusted EPS $1.15 vs. $1.14 consensus and revenue $11.16B (up 7.8% y/y), supported by cancer-diagnostics and medical-device strength. Abbott first-quarter results beat on cancer diagnostics, medical device strength
• Positive Sentiment: Exact Sciences acquisition expands Abbott into high-growth oncology diagnostics and is presented as strategic long-term growth even though it creates near-term EPS dilution. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
• Positive Sentiment: Broker support and insider activity: RBC Capital reaffirmed its buy rating and company insiders added shares, both signals of continued institutional/management confidence. RBC Capital Reaffirms Their Buy Rating on Abbott Laboratories (ABT) Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings
• Negative Sentiment: Guidance cut and dilution: Abbott lowered FY2026 adjusted EPS to $5.38–$5.58 (includes ~$0.20/share dilution from Exact Sciences) and Q2 EPS to $1.25–$1.31, below Street expectations — the guidance hit is the primary reason investors sold shares. Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
• Negative Sentiment: Margin pressure and weak Nutrition segment: management flagged margin compression and a prolonged slump in nutrition sales (plus a milder flu season that hurt consumer-test volumes), which weigh on near-term profit recovery. Abbott Stock Falls Despite Q1 Earnings & Revenue Beat Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
• Negative Sentiment: Market reaction: Despite the beat, investors focused on the weaker guide and merger-related costs, sending the stock lower (coverage pieces and commentaries explain the selloff). Why Abbott Laboratories Stock Tumbled on Thursday

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in shares of Abbott Laboratories by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock valued at $2,936,141,000 after buying an additional 188,616 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Abbott Laboratories by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock valued at $1,652,517,000 after buying an additional 52,191 shares in the last quarter. Amundi raised its stake in shares of Abbott Laboratories by 28.3% in the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock valued at $1,025,578,000 after buying an additional 1,803,975 shares in the last quarter. Raymond James Financial Inc. raised its stake in shares of Abbott Laboratories by 2.0% in the 3rd quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock valued at $741,515,000 after buying an additional 107,843 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Abbott Laboratories by 29.7% in the 4th quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after buying an additional 1,193,410 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.